News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
782,732 Results
Type
Article (55661)
Company Profile (356)
Press Release (726701)
Multimedia
Podcasts (139)
Webinars (22)
Section
Business (218636)
Career Advice (2898)
Deals (37824)
Drug Delivery (139)
Drug Development (87120)
Employer Resources (186)
FDA (17551)
Job Trends (16219)
News (372083)
Policy (36312)
Tag
2027 Biotech Bay Standard (2)
2027 Genetown Elite (2)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (3)
Academia (2925)
Academic (1)
Accelerated approval (33)
Adcomms (34)
Allergies (154)
Alliances (53629)
ALS (183)
Alzheimer's disease (1782)
Antibody-drug conjugate (ADC) (342)
Approvals (17751)
Artificial intelligence (575)
Autoimmune disease (164)
Automation (40)
Bankruptcy (389)
Best Places to Work (12220)
BIOSECURE Act (21)
Biosimilars (201)
Biotechnology (214)
Bladder cancer (163)
Brain cancer (63)
Breast cancer (668)
Cancer (5052)
Cardiovascular disease (438)
Career advice (2454)
Career pathing (41)
CAR-T (303)
CDC (54)
Celiac Disease (2)
Cell therapy (803)
Cervical cancer (37)
Clinical research (73979)
Collaboration (1825)
Company closure (4)
Compensation (1174)
Complete response letters (72)
COVID-19 (2932)
CRISPR (98)
C-suite (908)
Cystic fibrosis (150)
Data (6352)
Decentralized trials (2)
Denatured (40)
Depression (149)
Diabetes (527)
Diagnostics (7067)
Digital health (51)
Diversity (13)
Diversity, equity & inclusion (46)
Drug discovery (273)
Drug pricing (218)
Drug shortages (33)
Duchenne muscular dystrophy (245)
Earnings (93276)
Editorial (67)
Employer branding (23)
Employer resources (164)
Events (125373)
Executive appointments (1042)
FDA (20748)
Fibrodysplasia Ossificans Progressiva (6)
Friedreich's ataxia (11)
Frontotemporal dementia (23)
Funding (1537)
Gene editing (212)
Generative AI (49)
Gene therapy (657)
GLP-1 (1097)
Government (5182)
Grass and pollen (8)
Guidances (386)
Healthcare (20187)
HIV (63)
Huntington's disease (48)
IgA nephropathy (86)
Immunology and inflammation (289)
Immuno-oncology (64)
Indications (111)
Infectious disease (3222)
Inflammatory bowel disease (204)
Inflation Reduction Act (15)
Influenza (122)
Intellectual property (256)
Interviews (558)
IPO (17247)
IRA (59)
Job creations (4349)
Job search strategy (2000)
JPM (68)
Kidney cancer (18)
Labor market (86)
Layoffs (626)
Leadership (41)
Legal (9018)
Liver cancer (99)
Longevity (15)
Lung cancer (683)
Lymphoma (383)
Machine learning (44)
Management (64)
Manufacturing (840)
MASH (177)
Medical device (14439)
Medtech (14494)
Mergers & acquisitions (21654)
Metabolic disorders (1380)
Multiple sclerosis (169)
NASH (23)
Neurodegenerative disease (353)
Neuropsychiatric disorders (103)
Neuroscience (3107)
Neurotech (1)
NextGen: Class of 2026 (7165)
Non-profit (4929)
Now hiring (67)
Obesity (662)
Opinion (319)
Ovarian cancer (169)
Pain (217)
Pancreatic cancer (236)
Parkinson's disease (297)
Partnered (34)
Patents (514)
Patient recruitment (508)
Peanut (61)
People (64226)
Pharmaceutical (92)
Pharmacy benefit managers (31)
Phase 1 (22957)
Phase 2 (32395)
Phase 3 (24293)
Pipeline (5392)
Policy (328)
Postmarket research (2971)
Preclinical (9827)
Press Release (71)
Prostate cancer (250)
Psychedelics (58)
Radiopharmaceuticals (293)
Rare diseases (924)
Real estate (6628)
Recruiting (77)
Regulatory (26812)
Reports (53)
Research institute (2644)
Resumes & cover letters (457)
Rett syndrome (28)
RNA editing (18)
RSV (82)
Schizophrenia (160)
Series A (255)
Series B (198)
Service/supplier (13)
Sickle cell disease (103)
Special edition (25)
Spinal muscular atrophy (170)
Sponsored (44)
Startups (3967)
State (2)
Stomach cancer (20)
Supply chain (111)
Tariffs (99)
The Weekly (97)
Vaccines (1121)
Venture capital (96)
Weight loss (444)
Women's health (92)
Worklife (21)
Date
Today (163)
Last 7 days (614)
Last 30 days (2214)
Last 365 days (31369)
2026 (3556)
2025 (31645)
2024 (36822)
2023 (41747)
2022 (52983)
2021 (57653)
2020 (56522)
2019 (49805)
2018 (37727)
2017 (34736)
2016 (34708)
2015 (40739)
2014 (34848)
2013 (30228)
2012 (32211)
2011 (32823)
2010 (31018)
Location
Africa (965)
Alabama (86)
Alaska (7)
Arizona (325)
Arkansas (14)
Asia (45379)
Australia (8005)
California (11514)
Canada (3333)
China (1174)
Colorado (485)
Connecticut (487)
Delaware (345)
Europe (99846)
Florida (1705)
Georgia (365)
Hawaii (3)
Idaho (65)
Illinois (925)
India (70)
Indiana (536)
Iowa (23)
Japan (442)
Kansas (129)
Kentucky (40)
Louisiana (26)
Maine (72)
Maryland (1428)
Massachusetts (8336)
Michigan (336)
Minnesota (656)
Mississippi (6)
Missouri (139)
Montana (34)
Nebraska (28)
Nevada (125)
New Hampshire (83)
New Jersey (3054)
New Mexico (31)
New York (3042)
North Carolina (1557)
North Dakota (9)
Northern California (5607)
Ohio (340)
Oklahoma (22)
Oregon (47)
Pennsylvania (2321)
Puerto Rico (25)
Rhode Island (49)
South America (1342)
South Carolina (67)
South Dakota (1)
Southern California (4475)
Tennessee (178)
Texas (1787)
United States (41139)
Utah (344)
Vermont (1)
Virginia (283)
Washington D.C. (86)
Washington State (958)
West Virginia (4)
Wisconsin (115)
Wyoming (2)
782,732 Results for "respirerx formerly known as cortex pharmaceuticals inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
RespireRx Pharmaceuticals Inc. Announces Commencement of Rule 506(c) Private Placement
November 19, 2025
·
16 min read
Press Releases
RespireRx Pharmaceuticals Inc. Announces NIH/NINDS Grant Award and Amended and Restated Patent License Agreement
November 20, 2025
·
20 min read
Press Releases
RespireRx Pharmaceuticals Inc. Announces SEC Order Making Findings and Revoking Registration of Securities and Future Plans with respect to its Common Stock
November 19, 2025
·
17 min read
Business
RespireRx Pharmaceuticals Inc. Announces Agreement with Ponto Ventures to Drive Business Development with Will Clodfelter as RespireRx Part-Time Senior VP of Business Development
RespireRx Pharmaceuticals Inc. is pleased to announce that, on December 6, 2023, it has entered into an agreement with Ponto Ventures LLC providing for Will Clodfelter to serve as RespireRx’s Senior Vice President of Business Development on a part-time basis.
December 11, 2023
·
13 min read
Business
RespireRx Pharmaceuticals Inc. Announces the Appointment of Dr. Dariusz Naziek to Its Board of Directors
RespireRx Pharmaceuticals Inc. is pleased to announce the appointment of Dr. Dariusz Nasiek MD, MBA to its board of directors.
January 22, 2024
·
13 min read
Business
RespireRx Pharmaceuticals Inc. Announces a Department of Defense Award to Fund a Phase 2 Clinical Study to Determine the Safety and Efficacy of CX1739
RespireRx Pharmaceuticals Inc. is delighted to announce that the Department of Defense (DOD) has approved a $1.8 million translational research award to Shirley Ryan AbilityLab to fund a two stage Phase 2A and 2B clinical study.
May 29, 2024
·
15 min read
Pharm Country
RespireRx Pharmaceuticals Inc. Reports Preclinical Pain Relief for their Non-Opioid Lead GABAkine
RespireRx Pharmaceuticals Inc. is pleased to announce that KRM-II-81, its lead GABA A receptor potentiator (GABAkine), has advanced to the next level of evaluation within the NIH HEAL Initiative ® Preclinical Screening Platform for Pain.
February 13, 2024
·
15 min read
Business
RespireRx Pharmaceuticals Inc.’s Subsidiary ResolutionRx Ltd Enters into Master Services Agreement for Dronabinol Manufacturing and Related Services
RespireRx Pharmaceuticals Inc. are pleased to announce that on October 9, 2023, ResolutionRx entered into a Master Services Agreement (“MSA”) with Ab Initio Pharma Pty Ltd.
October 12, 2023
·
13 min read
Pharm Country
RespireRx Pharmaceuticals Inc. Announces the Publication of a Case Report in which KRM-II-81 Totally Suppressed Epileptiform Activity in Brain Tissue Surgically Removed from Epileptic Patient
RespireRx Pharmaceuticals Inc. (OTC Pink Market: RSPI) (“RespireRx” or the “Company”) is pleased to announce the publication of a case report in Heliyon, Cell Press’s peer-reviewed journal (available at https://www.cell.com/heliyon/pdf/S2405-8440(23)10960-1.pdf) involving a 19-year old patient with pharmaco-resistant epilepsy.
January 4, 2024
·
14 min read
Pharm Country
RespireRx Pharmaceuticals Inc. Reports Publication of Preclinical Research Results Demonstrating the Ability of CX1739, its Lead Clinical AMPAkine, to Improve Bladder Function After Spinal Cord Injury
RespireRx Pharmaceuticals Inc. is pleased to announce that, as part of an ongoing collaboration, a scientist team led by Dr. David Fuller of the University of Florida has published a peer-reviewed research article describing the ability of CX1739.
March 20, 2024
·
14 min read
1 of 78,274
Next
